Sulfadiazine
Neotrizine, Sulfadiazine, Sulfonamides Duplex (sulfadiazine) is a small molecule pharmaceutical. Sulfadiazine was first approved as Sulfadiazine on 1982-01-01. It is used to treat aids-related opportunistic infections, bacterial infections, chancroid, enterobacteriaceae infections, and malaria amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Sulfadiazine (discontinued: Sulfadiazine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulfadiazine
Sulfadiazine sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SULFADIAZINE SODIUM | Lederle Laboratories | N-004054 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| silvadene | New Drug Application | 2026-01-26 |
| silver sulfadiazene | New Drug Application | 2018-04-19 |
| silver sulfadiazine | New Drug Application | 2026-03-17 |
| ssd | New Drug Application | 2024-11-08 |
| ssd cream | New Drug Application | 2025-09-22 |
| ssdc alphasan hand sanitizer | C200263 | 2025-12-31 |
| ssdc antibacterial foam handsoap | C200263 | 2026-03-03 |
| ssdc foaming hand sanitizer | C200263 | 2026-03-04 |
| ssdc gel hand sanitizer | C200263 | 2026-03-04 |
| ssdc mystic foaming hand sanitizer | C200263 | 2025-12-17 |
Show 2 more
Indications
FDA
EMA
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BA: Sulfonamides, topical
— D06BA01: Silver sulfadiazine
— D06BA51: Silver sulfadiazine, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01E: Sulfonamides and trimethoprim antibacterials for systemic use
— J01EC: Intermediate-acting sulfonamides
— J01EC02: Sulfadiazine
— J01EE: Combinations of sulfonamides and trimethoprim, incl. derivatives
— J01EE02: Sulfadiazine and trimethoprim
— J01EE06: Sulfadiazine and tetroxoprim
HCPCS
No data
Clinical
Clinical Trials
243 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Burns | D002056 | — | T30.0 | — | 6 | 5 | 5 | 10 | 24 |
| Unilateral hearing loss | D046088 | — | — | — | — | — | 1 | 10 | 11 |
| Communicable diseases | D003141 | — | — | 2 | 3 | 1 | 2 | — | 6 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 2 | — | 1 | 3 | 6 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 1 | 1 | — | 4 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | — | — | 1 | 1 | 4 |
| Toxoplasmosis | D014123 | EFO_0007517 | B58 | — | 1 | — | 2 | 1 | 4 |
| Immune system diseases | D007154 | — | D89.9 | 2 | 2 | — | 1 | — | 3 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | 1 | — | 2 |
| Rare diseases | D035583 | — | — | 1 | 1 | — | 1 | — | 2 |
Show 14 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatic encephalopathy | D006501 | — | K72.91 | — | 1 | 2 | — | — | 3 |
| Articulation disorders | D001184 | — | F80.0 | — | 1 | 1 | — | 2 | 3 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | 1 | 2 | 1 | — | — | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 1 | — | 1 | 2 |
| Communication disorders | D003147 | — | F80.9 | — | 1 | 1 | — | 1 | 2 |
| Chorioretinitis | D002825 | — | H30 | — | — | 1 | — | — | 1 |
| Eye burns | D005126 | EFO_1001788 | — | — | 1 | 1 | — | — | 1 |
| Congenital toxoplasmosis | D014125 | EFO_0007220 | P37.1 | — | — | 1 | — | — | 1 |
| Dyslexia | D004410 | EFO_0005424 | F81.0 | — | 1 | 1 | — | — | 1 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Speech sound disorder | D066229 | — | — | 3 | 1 | — | — | 19 | 22 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 1 | — | — | 1 | 5 |
| Somatoform disorders | D013001 | — | F45 | — | 1 | — | — | 4 | 5 |
| Hodgkin disease | D006689 | — | C81 | 2 | 1 | — | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 2 | — | — | — | 3 |
| Sarcoma | D012509 | — | — | 3 | 1 | — | — | — | 3 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | 3 | 1 | — | — | — | 3 |
| Radiodermatitis | D011855 | — | L58 | — | 1 | — | — | 2 | 3 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | 2 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 2 | 3 |
Show 48 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Speech | D013060 | — | — | 1 | — | — | — | 3 | 4 |
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | 1 | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | 1 | — | — | — | — | 1 |
| Cytomegalovirus retinitis | D017726 | EFO_1001302 | — | 1 | — | — | — | — | 1 |
| Retinitis | D012173 | — | H30.9 | 1 | — | — | — | — | 1 |
Show 15 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Electroacupuncture | D015671 | — | — | — | — | — | — | 8 | 8 |
| Hearing loss | D034381 | EFO_0004238 | H91.9 | — | — | — | — | 7 | 7 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | — | — | 5 | 5 |
| Deafness | D003638 | EFO_0001063 | H91.9 | — | — | — | — | 5 | 5 |
| Speech disorders | D013064 | — | F80.81 | — | — | — | — | 4 | 4 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 4 | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 4 | 4 |
| Conductive hearing loss | D006314 | — | H90.2 | — | — | — | — | 3 | 3 |
| Apraxias | D001072 | — | R48.2 | — | — | — | — | 3 | 3 |
| Fibrosis | D005355 | — | — | — | — | — | — | 3 | 3 |
Show 131 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sulfadiazine |
| INN | sulfadiazine sodium |
| Description | Sulfadiazine is a sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position. It has a role as an antimicrobial agent, an antiinfective agent, a coccidiostat, an antiprotozoal drug, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor, an EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of pyrimidines, a sulfonamide, a substituted aniline and a sulfonamide antibiotic. It is functionally related to a sulfanilamide. It is a conjugate acid of a sulfadiazinate. |
| Classification | Small molecule |
| Drug class | antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 68-35-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL439 |
| ChEBI ID | 9328 |
| PubChem CID | 5215 |
| DrugBank | DB00359 |
| UNII ID | 84CS1P306F (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Sulfadiazine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,306 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use